J. Schornagel

发表

How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues.

N. Aaronson, M. Muller, S. Detmar, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical pharmacology of methotrexate.

J. Schornagel, J. Mcvie, 1983, Cancer treatment reviews.

Major and minor salivary glands tumours.

P. Bruzzi, J. Schornagel, L. Licitra, 2003, Critical reviews in oncology/hematology.

Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.

Y. Assaraf, J. Schornagel, D. Priest, 1997, Advances in enzyme regulation.

The patient-physician relationship. Patient-physician communication during outpatient palliative treatment visits: an observational study.

N K Aaronson, N. Aaronson, M. Muller, 2001, JAMA.

Gene amplification and altered enzymes as mechanisms for the development of drug resistance.

J. Schornagel, S. Srimatkandada, J. Bertino, 1983, Cancer treatment reports.

Endocytosis of GPI-linked membrane folate receptor-alpha

G J Strous, J. Schornagel, G. Jansen, 1996, The Journal of cell biology.

Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.

G. Peters, G. Giaccone, J. Schornagel, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.

J. Schornagel, D. Newell, G. Jansen, 1990, Cancer research.

A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance*

G. Peters, Y. Assaraf, J. Schornagel, 1998, The Journal of Biological Chemistry.

The formation and persistence of carboplatin-DNA adducts in rats

J. Schornagel, F. A. Blommaert, L. den Engelse, 1996, Cancer Chemotherapy and Pharmacology.

Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro.

M. Ruevekamp, J. Schornagel, A. Begg, 1994, Cancer research.

Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.

J. Schornagel, G. Jansen, G. Rijksen, 1990, The Journal of biological chemistry.

Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines.

J. Schornagel, G. Jansen, G. Westerhof, 1992, Advances in enzyme regulation.

Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.

J. Schornagel, G. Jansen, G. Peters, 1995, Cancer research.

M. Piccart, C. Gotay, A. Bottomley, 2005, The Lancet. Oncology.

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.

M. Piccart, R. Paridaens, J. Schornagel, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Concurrent chemotherapy and radiation for locally advanced squamous cell cancers: what is the schedule of choice?

H. Bartelink, J. Schornagel, M. Verheij, 2001, Current oncology reports.

Comparison of breast cancer mucin (BCM) and CA 15-3 in human breast cancer

M. A. Blankenstein, J. Nortier, J. Schornagel, 1990, Breast Cancer Research and Treatment.

The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors

G. Peters, G. Giaccone, J. Schellens, 2004, Clinical Cancer Research.

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors

G. Peters, G. Giaccone, J. Wanders, 2003, Cancer Chemotherapy and Pharmacology.

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

L. Collette, J. Witjes, C. Sternberg, 2006, European journal of cancer.

Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.

W. Dreschler, J. Schornagel, C. Rasch, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Detergent-insolubility during the biosynthesis of membrane folate receptor-2.

J. Schornagel, G. Jansen, G. Posthuma, 1993, Advances in experimental medicine and biology.

Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

F. Hoebers, M. Hauptmann, J. Schornagel, 2010, Cancer.

Chronic cardiotoxicity of adriamycin studied in a rat model by 31P NMR

W. D. de Jong, T. Ruigrok, J. Schornagel, 1991, NMR in biomedicine.

Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate

J. Schornagel, G. Jansen, C. Molthoff, 1996, Cancer Chemotherapy and Pharmacology.

Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-ARM randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)

J. Schornagel, J. Jassem, W. Nooijen, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer.

J. Schornagel, W. Meinhardt, H. van Tinteren, 2005, The Journal of urology.

Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.

A. Hart, J. Schornagel, F. Muggia, 1993, Cancer research.

Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size.

S. Rodenhuis, O. Dalesio, D. Richel, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP

S. Rodenhuis, J. Verweij, J. Schornagel, 1999, International journal of cancer.

Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.

S. Rodenhuis, D. Richel, J. Schornagel, 1995, Cancer investigation.

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.

S. Rodenhuis, J. Baars, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.

S. Rodenhuis, J. Baars, J. Schornagel, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The formation and repair of cisplatin-DNA adducts in wild-type and cisplatin-resistant L1210 cells: comparison of immunocytochemical determination with detection in isolated DNA.

R. Baan, J. Schornagel, B. Floot, 1998, Chemico-biological interactions.

Immunocytochemical Analysis of Platinum-DNA Adducts

J. Schornagel, F. A. Blommaert, L. Engelse, 1991 .

Combination treatment of cis- and carboplatin in cancers restricted to the peritoneal cavity in the rat

J. Schornagel, H. Pinedo, M. Vugt, 2004, Cancer Chemotherapy and Pharmacology.

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors

L. Collette, S. Fosså, C. Sternberg, 2005 .

Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.

G. Peters, J. Schornagel, A. Jackman, 1995, Molecular pharmacology.

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Schornagel, A. Westermann, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of primary tumor volume after concurrent chemoradiation with daily low‐dose cisplatin for advanced‐stage head and neck carcinoma

F. Hoebers, J. Schornagel, C. Rasch, 2008, Head and Neck.

Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer.

M. Hauptmann, J. Schornagel, C. Rasch, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.

A. Hart, W. Dreschler, J. Schornagel, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma.

F. Hoebers, J. Schornagel, C. Rasch, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Plenary 2 : Intra-Arterial Versus Intravenous Chemoradiation for Advanced Head and Neck Cancer, Early Results of a Multi-institutional Trial

D. Rietveld, J. Schornagel, R. Wiggenraad, 2006 .

High‐dose superselective intra‐arterial cisplatin and concomitant radiation (radplat) for advanced head and neck cancer

I. Tan, J. Schornagel, C. Rasch, 2004, Head & neck.

Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer.

S. Rodenhuis, J. Wanders, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer.

S. Rodenhuis, J. Schornagel, J. Sein, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypersensitivity Reactions to Etoposide

J. Beijnen, J. Schornagel, R. Hoetelmans, 1996, The Annals of pharmacotherapy.

Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems.

J. Schornagel, G. Jansen, A. Jackman, 1991, Cancer research.

Expression of a folate binding protein in L1210 cells grown in low folate medium.

J. Schornagel, G. Jansen, B. Braakhuis, 1989, Cancer research.

Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate.

J. Schornagel, G. Jansen, G. Peters, 1994, Biochemical pharmacology.

Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin

J. Schornagel, P. Steerenberg, W. H. Jong, 2004, Cancer Chemotherapy and Pharmacology.

REVIEW OF CARBOPLATIN-BASED HIGH-DOSE CHEMOTHERAPY COMBINATIONS IN THE AUTOTRANSPLANT SETTING

S. Rodenhuis, J. Baars, J. Schornagel, 1996 .

Value of caregiver ratings in evaluating the quality of life of patients with cancer.

N. Aaronson, M. Sprangers, S. Detmar, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.

J. Schornagel, R. V. Valdés Olmos, C. Hoefnagel, 1991, Journal of nuclear biology and medicine.

Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.

G. Peters, Y. Assaraf, J. Schornagel, 2002, Biochemical pharmacology.

The reduced folate/methotrexate carrier and a membrane-associated folate binding protein as transport routes for novel antifolates: structure-activity relationships.

J. Schornagel, G. Jansen, A. Jackman, 1993, Advances in experimental medicine and biology.

Synthesis and evaluation of 2,4-diaminoquinazoline antifolates with activity against methotrexate-resistant human tumor cells.

J. Schornagel, J. Bertino, E. Mini, 1984, Biochemical pharmacology.

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2

J. Schornagel, H. Pinedo, 1996, Springer US.

Resistance to methotrexate due to gene amplification in a patient with acute leukemia.

J. Schornagel, S. Srimatkandada, J. Bertino, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Membrane transport of methotrexate in a squamous carcinoma cell line adapted to low folate concentrations.

J. Schornagel, G. Hordijk, G. Jansen, 1991, Anticancer research.

Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.

J. Schornagel, G. Jansen, G. Rijksen, 1989, Cancer research.

High performance liquid chromatography of plasma pyrimidines and purines and its application in cancer chemotherapy.

J. Schornagel, H. Pinedo, A. Leyva, 1979, Advances in experimental medicine and biology.

Is there a role for thymidine in cancer chemotherapy?

J. Schornagel, H. Pinedo, A. Leyva, 1982, Cancer treatment reviews.

Clinical and biochemical studies of high-dose thymidine treatment in patients with solid tumors

J. Schornagel, S. K. Wadman, H. Pinedo, 2005, Journal of Cancer Research and Clinical Oncology.

Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules.

J. Schornagel, G. Hordijk, G. Jansen, 1991, European journal of cancer.

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

J. Klijn, J. Verweij, J. Schornagel, 1989, Journal of Urology.

Influence of concomitant infusion of thymidine and inosine on methotrexate activity in normal and P388-bearing mice.

J. Schornagel, H. Pinedo, A. Leyva, 1984, European journal of cancer & clinical oncology.

Synergism between purines and thymidine (TDR) in reversal of methotrexate (MTX) toxicity in mice using continuous infusions.

J. Schornagel, H. Pinedo, A. Leyva, 1984, Advances in experimental medicine and biology.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

A. Graeff, J. Verweij, J. Schornagel, 1996 .

Diagnosis and treatment of isolated neck metastases of adenocarcinomas.

J. Schornagel, F. Hilgers, M. V. van Velthuysen, 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

J. Verweij, J. Schornagel, F. Cognetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of mitozolomide on a once daily for 5 days schedule

J. Schornagel, J. Mcvie, W. W. Huinink, 1990, Cancer Chemotherapy and Pharmacology.

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

L. Collette, C. Sternberg, J. Schornagel, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours.

S. Rodenhuis, O. Dalesio, A. te Velde, 1996, Anticancer research.

Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients.

N. Aaronson, M. Sprangers, S. Detmar, 1998, Journal of clinical epidemiology.

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

A. Graeff, J. Verweij, J. Schornagel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive cytoreductive therapy followed by autologous bone marrow transplantation for patients with hematologic malignancies or solid tumors

J. Schornagel, L. Verdonck, G. D. de Gast, 1987, Cancer.

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

J. Peterse, S. Rodenhuis, J. Baars, 1998, The Lancet.

Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure.

J. Schornagel, G. Hordijk, G. Jansen, 1992, Oncology research.

Bioanalysis of the investigational anti-tumour drug 5,10-dideaza-5,6,7,8-tetrahydrofolic acid by high-performance liquid chromatography with ultraviolet detection.

J. Beijnen, J. Schornagel, O. van Tellingen, 1992, Journal of chromatography.

High dose chemotherapy in breast cancer reviewed

S. Rodenhuis, J. Baars, J. Schornagel, 1995 .

Receptor-mediated Transport Systems Compounds in Murine L 1210 Leukemia Cells : Role of Carrier-Membrane Transport of Natural Folates and Antifolate

J. Schornagel, G. Jansen, A. Jackman, 2006 .

A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

J. Verweij, J. Schornagel, J. Armand, 1992 .

Lack of effect of methotrexate on human head and neck tumours transplanted in athymic nude mice.

G. Snow, J. Schornagel, B. Braakhuis, 1985, Acta oto-laryngologica.

Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma

L. Zijp, J. Schornagel, C. Rasch, 2004, Cancer.

Erratum: Intra‐arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial

M. Hauptmann, J. Schornagel, R. Wiggenraad, 2022 .

Cisplatin‐based chemotherapy in advanced adenoid cystic carcinoma of the head and neck

J. Verweij, J. Schornagel, P. D. De Mulder, 1992, Head & neck.

Synthesis and biological evaluation of a fluorescent analogue of folic acid.

J. Schornagel, S. Patil, S. Kerwar, 1991, Biochemistry.

N. Aaronson, M. Sprangers, S. Detmar, 2022 .

Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.

J. Schellens, J. Beijnen, J. Schornagel, 2006, British journal of clinical pharmacology.

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

J. Schellens, H. Rosing, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Beijnen, J. Schornagel, W. W. ten Bokkel Huinink, 2006, British Journal of Cancer.

The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.

S. Rodenhuis, J. Baars, D. Richel, 1996, European journal of cancer.

N. Aaronson, M. Muller, S. Detmar, 2002, JAMA.

Transformation of an L-cell line with the DNA coding for the reduced-folate/methotrexate transporter protein from a CCRF-CEM human leukemia cell line.

J. Schornagel, G. Jansen, M. Ratnam, 1993, Advances in experimental medicine and biology.

Interaction of N-hydroxy(sulfo) succinimide active esters with the reduced folate/methotrexate transport system from human leukemic CCRF-CEM cells.

J. Schornagel, G. Jansen, G. Rijksen, 1989, Biochimica et biophysica acta.

Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake.

J. Schornagel, G. Jansen, G. Rijksen, 1989, Leukemia research.

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.

J. Verweij, J. Schornagel, A. de Graeff, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Toxic dermatitis induced by 10‐ethyl‐10‐deazaaminopterin (10‐EdAM), a novel antifolate

J. Verweij, J. Schornagel, F. Cognetti, 1990, Cancer.

Identification of a reduced folate/methotrexate carrier in human KB-cells expressing high levels of membrane associated folate binding protein.

J. Schornagel, G. Jansen, G. Westerhof, 1993, Advances in experimental medicine and biology.

Clinical pharmacokinetics of anti-metabolites.

J. Schornagel, G. Milano, G. Peters, 1993, Cancer surveys.

Characterization of receptor-mediated (anti)folate uptake in human CCRF-CEM cells

J. Schornagel, G. Jansen, G. Rijksen, 1990 .

Role of health-related quality of life in palliative chemotherapy treatment decisions.

N. Aaronson, M. Muller, S. Detmar, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-Physician Communication During Outpatient Palliative Treatment Visits: An Observational Study

N. Aaronson, M. Muller, S. Detmar, 2001 .

Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma.

J. Schornagel, C. Rasch, F. Hilgers, 2002, Archives of otolaryngology--head & neck surgery.

Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma.

P. van den Broek, J. Verweij, J. Schornagel, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

A phase 1 and pharmacokinetic study using the aromatic retinoic acid analogue dichloroetretinate (Ro 12-7554)

J. Schornagel, A. Struyvenberg, B. Zonnenberg, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 2004, Cancer Chemotherapy and Pharmacology.

Variant GPI structure in relation to membrane-associated functions of a murine folate receptor.

J. Schornagel, J. Ross, M. Ratnam, 1996, Biochemistry.

Short communication A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 1994 .

Induction Chemotherapy with Cisplatin and Continuous Infusion 5‐Fluorouracil in Locally Far‐Advanced Head and Neck Cancer

G. Snow, J. Verweij, J. Schornagel, 1989, American Journal of Clinical Oncology.

Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure

Willem Boogerd, Jos H. Beijnen, J. Schellens, 2001, Cancer Chemotherapy and Pharmacology.

Immunocytoma Cisplatin-sensitive or-resistant Immunoglobulin M and Organs of Cisplatin-treated LOU / M Rats Inoculated with Platinum Concentrations and DNA Adduct Levels in Tumors

J. Schornagel, P. Steerenberg, G. Groot, 2006 .

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

J. Peterse, S. Rodenhuis, J. Baars, 1996, British Journal of Cancer.

Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer.

J. Peterse, S. Rodenhuis, D. Richel, 1993, Annals of Oncology.

940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E)

S. Rodenhuis, J. Beijnen, J. Schornagel, 1995 .

Bioavailability of methotrexate tablets

J. Schornagel, M. V. Engelen, D. Vos, 1982, Pharmaceutisch Weekblad.

Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses

N. Aaronson, S. Detmar, J. Schornagel, 1999 .

Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.

A. Hart, W. Dreschler, J. Schornagel, 2007, International journal of radiation oncology, biology, physics.

In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate

J. Schornagel, G. Hordijk, G. Jansen, 1992, International journal of cancer.

Occurrence and significance of D-methotrexate as a contaminant of commercial methotrexate.

S. Cramer, J. Schornagel, J. Bertino, 1984, Cancer research.

Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up.

M. J. van de Vijver, J. Peterse, S. Rodenhuis, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Mechanisms of resistance against methotrexate and novel antifolates in human CCRF-CEM leukemia cells

G. Peters, J. Schornagel, G. Jansen, 1997 .

At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies.

S. Rodenhuis, J. Baars, J. Schornagel, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer

J. Schornagel, M. Schot, H. Helgason, 2006, British Journal of Cancer.